Business, energy, technology, markets and global industry news from Business News Today

Tralesinidase Alfa

PharmaDeviceNews Tralesinidase Alfa
Editorial infographic highlighting Spruce Biosciences’ MPS IIIB disease progression research, featuring neurological imagery, enzyme therapy molecular models and laboratory equipment, with key milestones for TA-ERT development, a planned FDA filing and a confirmatory clinical trial.
Pharma & Biotech

Can Spruce Biosciences prove its Sanfilippo treatment slows brain decline? New data could strengthen its FDA case

Spruce Biosciences prepares MPS IIIB disease progression data as TA-ERT approaches its FDA filing and confirmatory trial milestones.

Read More
Representative image: A pediatric neurology research setting highlights the clinical focus on tralesinidase alfa, enzyme replacement therapy, and long-term treatment advances for Sanfilippo syndrome type B.
Pharma & Biotech

Could Spruce Biosciences finally change the Sanfilippo syndrome type B treatment landscape?

Spruce Biosciences’ MPS IIIB data raise a pivotal question: can tralesinidase alfa turn biomarker gains into disease-changing therapy?

Read More